Outcomes at > 3 to 6 months after ablation · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence of atrial tachyarrhythmias · Human trial participants undergoing ablation for atrial fibrillation
Class III antiarrhythmics showed no clear difference in recurrence of atrial tachyarrhythmias compared with control (low certainty).
1 finding from 1 review
Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation
It is very uncertain whether class III antiarrhythmics changes adverse events: thromboembolic events compared with control (very low certainty).
1 finding from 1 review
Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation
It is very uncertain whether class III antiarrhythmics changes all‐cause mortality compared with control (very low certainty).
1 finding from 1 review
Requirement for 1 or more repeat ablation · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
Outcomes at > 3 to 6 months after ablation · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence of atrial tachyarrhythmias · Human trial participants undergoing ablation for atrial fibrillation
Class I and/or III antiarrhythmics probably leads to lower recurrence of atrial tachyarrhythmias compared with control (moderate certainty).
1 finding from 1 review
Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation
It is very uncertain whether class I and/or III antiarrhythmics changes adverse events: thromboembolic events compared with control (very low certainty).
1 finding from 1 review
Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation
Class I and/or III antiarrhythmics showed no clear difference in all‐cause mortality compared with control (low certainty).
1 finding from 1 review
Requirement for 1 or more repeat ablation · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported